Experimental
Mazdutide (IBI362)
The prediction game
Call it: rising or fading?
Where does Mazdutide (IBI362) stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: C (mixed evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.6/10
Mazdutide earns a neutral score because the science is strong but the access and cardiac questions are not yet resolved. If your specific goal is liver fat, mazdutide posts the best published incretin numbers anywhere, roughly 72 to 80 percent reduction, per Ji 2025, and that is a real reason to watch this drug closely. For general weight loss, the honest call is that FDA-approved tirzepatide delivers comparable results with a prescription, pharmaceutical-grade quality, and cardiovascular outcomes data mazdutide does not have. The biggest cautions are the China-only approval, the grey-market reality in the West, and the glucagon-driven heart-rate signal that makes misdosing higher-stakes than with a pure GLP-1. ✅ Best for: People whose primary target is liver fat, where mazdutide's glucagon-driven hepatic effect is genuinely differentiated. Researchers and informed self-experimenters tracking the dual-agonist class who understand the data is Chinese-population-only. Anyone who can source verified pharmaceutical-grade material rather than untested powder, and who will monitor heart rate, glucose, and liver enzymes through dosing. People without cardiac risk factors, since the heart-rate effect matters most for those starting with a fast or borderline pulse. ❌ Avoid if: You have a personal or family history of medullary thyroid cancer, because of the class C-cell tumor warning. You have a history of pancreatitis, given the class pancreatitis signal. You have meaningful cardiovascular disease or arrhythmia, since the glucagon leg raises heart rate and no cardiovascular outcomes trial has cleared it. You want a legal, prescribable option with quality control, in which case approved alternatives fit better. You cannot verify source quality, because grey-market contamination risk compounds the drug's own glucagon-driven dangers.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 0.0%
- BioHarmony Score
- 5.6/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.